EULAV Asset Management Sells 3,000 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

EULAV Asset Management decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,500 shares of the pharmaceutical company’s stock after selling 3,000 shares during the period. EULAV Asset Management’s holdings in Vertex Pharmaceuticals were worth $11,477,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Northwest Investment Counselors LLC purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter worth $27,000. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at $30,000. Finally, Legacy Investment Solutions LLC bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 2.5 %

Shares of VRTX stock opened at $469.32 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a 50 day simple moving average of $435.84 and a two-hundred day simple moving average of $462.87.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VRTX. Truist Financial decreased their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the company from $500.00 to $550.00 in a report on Monday, December 9th. Scotiabank upped their price target on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research note on Friday, January 31st. Bank of America lowered their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. Finally, Citigroup assumed coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $502.58.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.